Analysis of Risk Factors for Distant Metastasis of Pancreatic Ductal Adenocarcinoma Without Regional Lymph Node Metastasis and a Nomogram Prediction Model for Survival

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2023 Mar 3

PMID 36865748

Authors

Jinsheng Huang

Xujia Li

Qi Jiang

Huijuan Qiu

Yuming Rong

Bokang Cui

Guifang Guo

Affiliations

Soon will be listed here.

Abstract

Background: Negative regional lymph nodes do not indicate a lack of distant metastasis. A considerable number of patients with negative regional lymph node pancreatic cancer will skip the step of regional lymph node metastasis and directly develop distant metastasis.

Methods: We retrospectively analyzed the clinicopathological characteristics of patients with negative regional lymph node pancreatic cancer and distant metastasis in the Surveillance, Epidemiology, and End Results database from 2010 to 2015. Multivariate logistic analysis and Cox analysis were used to determine the independent risk factors that promoted distant metastasis and the 1-, 2-, and 3-year cancer-specific survival in this subgroup.

Results: Sex, age, pathological grade, surgery, radiotherapy, race, tumor location, and tumor size were significantly correlated with distant metastasis ( < 0.05). Among these factors, pathological grade II and above, tumor site other than the pancreatic head, and tumor size >40 mm were independent risk factors for distant metastasis; age ≥60 years, tumor size ≤21 mm, surgery, and radiation were protective factors against distant metastasis. Age, pathological grade, surgery, chemotherapy, and metastasis site were identified as predictors of survival. Among them, age ≥40 years, pathological grade II and above, and multiple distant metastasis were considered independent risk factors for cancer-specific survival. Surgery and chemotherapy were considered protective factors for cancer-specific survival. The prediction performance of the nomogram was significantly better than that of the traditional American Joint Committee on Cancer tumor, node, metastasis staging system. We also established an online dynamic nomogram calculator, which can predict the survival rate of patients at different follow-up time points.

Conclusion: Pathological grade, tumor location, and tumor size were independent risk factors for distant metastasis in pancreatic ductal adenocarcinoma with negative regional lymph nodes. Older age, smaller tumor size, surgery, and radiotherapy were protective factors against distant metastasis. A new nomogram that was constructed could effectively predict cancer-specific survival in pancreatic ductal adenocarcinoma with negative regional lymph nodes and distant metastasis. Furthermore, an online dynamic nomogram calculator was established.

Citing Articles

Accurate prediction of the lymph node status in ampullary duodenal carcinoma: potential guidance for clinical management.

Ni R, Zhang T, Mou Y, Hu Z, Gu Z BMC Cancer. 2024; 24(1):1363.

PMID: 39511526 PMC: 11542209. DOI: 10.1186/s12885-024-13119-3.

Nomogram for predicting the preoperative lymph node metastasis in resectable pancreatic cancer.

Cheng H, Xu J, Kang X, Liu X, Wang H, Wang Z J Cancer Res Clin Oncol. 2023; 149(13):12469-12477.

PMID: 37442865 PMC: 10465378. DOI: 10.1007/s00432-023-05048-8.

References

Feng T, Lv W, Yuan M, Shi Z, Zhong H, Ling S . Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma. World J Surg Oncol. 2019; 17(1):54. PMC: 6429809. DOI: 10.1186/s12957-019-1597-5. View

Lambert A, Pattabiraman D, Weinberg R . Emerging Biological Principles of Metastasis. Cell. 2017; 168(4):670-691. PMC: 5308465. DOI: 10.1016/j.cell.2016.11.037. View

Watanabe I, Sasaki S, Konishi M, Nakagohri T, Inoue K, Oda T . Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas. 2004; 28(2):160-5. DOI: 10.1097/00006676-200403000-00007. View

Gao Y, Bado I, Wang H, Zhang W, Rosen J, Zhang X . Metastasis Organotropism: Redefining the Congenial Soil. Dev Cell. 2019; 49(3):375-391. PMC: 6506189. DOI: 10.1016/j.devcel.2019.04.012. View

Kanda M, Fujii T, Nagai S, Kodera Y, Kanzaki A, Sahin T . Pattern of lymph node metastasis spread in pancreatic cancer. Pancreas. 2011; 40(6):951-5. DOI: 10.1097/MPA.0b013e3182148342. View

Hammel P, Huguet F, Van Laethem J, Goldstein D, Glimelius B, Artru P . Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016; 315(17):1844-53. DOI: 10.1001/jama.2016.4324. View

Durczynski A, Hogendorf P, Szymanski D, Grzelak P, Strzelczyk J . Sentinel lymph node mapping in tumors of the pancreatic body: preliminary report. Contemp Oncol (Pozn). 2013; 16(3):206-9. PMC: 3687406. DOI: 10.5114/wo.2012.29285. View

Bahardoust M, Abyazi M, Emami S, Ghadimi P, Khodabandeh M, Mahmoudi F . Predictors of survival rate in patients with pancreatic cancer: A multi-center analytical study in Iran. Cancer Rep (Hoboken). 2021; 5(8):e1547. PMC: 9351653. DOI: 10.1002/cnr2.1547. View

Fu N, Wang W, Cheng D, Wang J, Xu Z, Deng X . Original study: The rescue staging for pancreatic ductal adenocarcinoma with inadequate examined lymph nodes. Pancreatology. 2021; 21(4):724-730. DOI: 10.1016/j.pan.2021.02.010. View

10.

Vincent A, Herman J, Schulick R, Hruban R, Goggins M . Pancreatic cancer. Lancet. 2011; 378(9791):607-20. PMC: 3062508. DOI: 10.1016/S0140-6736(10)62307-0. View

11.

Stott M, Oldfield L, Hale J, Costello E, Halloran C . Recent advances in understanding pancreatic cancer. Fac Rev. 2022; 11:9. PMC: 9022729. DOI: 10.12703/r/11-9. View

12.

Wright G, Poruk K, Zenati M, Steve J, Bahary N, Hogg M . Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis. J Gastrointest Surg. 2016; 20(11):1830-1835. DOI: 10.1007/s11605-016-3256-2. View

13.

Maiborodin I, Mansurova A, Chernyavskiy A, Romanov A, Voitcitctkii V, Kedrova A . Cancer Angiogenesis and Opportunity of Influence on Tumor by Changing Vascularization. J Pers Med. 2022; 12(3). PMC: 8954734. DOI: 10.3390/jpm12030327. View

14.

Brennan M, Kattan M, Klimstra D, Conlon K . Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004; 240(2):293-8. PMC: 1356406. DOI: 10.1097/01.sla.0000133125.85489.07. View

15.

Okada K, Uemura K, Kondo N, Sumiyoshi T, Seo S, Otsuka H . Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. Pancreatology. 2021; 21(3):606-612. DOI: 10.1016/j.pan.2021.01.022. View

16.

Michelakos T, Pergolini I, Fernandez-Del Castillo C, Honselmann K, Cai L, Deshpande V . Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2017; 269(4):733-740. DOI: 10.1097/SLA.0000000000002600. View

17.

Dreyer S, Jamieson N, Upstill-Goddard R, Bailey P, McKay C, Biankin A . Defining the molecular pathology of pancreatic body and tail adenocarcinoma. Br J Surg. 2018; 105(2):e183-e191. PMC: 5817249. DOI: 10.1002/bjs.10772. View

18.

Shi Y, Liu B, Li X, Zhu H, Wei Y, Zhao B . Establishment of a multi-parameters MRI model for predicting small lymph nodes metastases (<10 mm) in patients with resected pancreatic ductal adenocarcinoma. Abdom Radiol (NY). 2021; 47(9):3217-3228. PMC: 9388457. DOI: 10.1007/s00261-021-03347-7. View

19.

Torphy R, Fujiwara Y, Schulick R . Pancreatic cancer treatment: better, but a long way to go. Surg Today. 2020; 50(10):1117-1125. PMC: 7837389. DOI: 10.1007/s00595-020-02028-0. View

20.

Parmar A, Vargas G, Tamirisa N, Sheffield K, Riall T . Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. Surgery. 2014; 156(2):280-9. PMC: 4099282. DOI: 10.1016/j.surg.2014.03.001. View